Gentler dosing tested for tough liver cancer treatment
NCT ID NCT05622136
Summary
This study is testing a new way of giving an existing liver cancer drug called regorafenib. The goal is to see if starting with a lower dose and slowly increasing it over the first two months helps patients better tolerate the treatment and stay on it longer. It involves 28 people with advanced liver cancer that has worsened after their first treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICESP - Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, 01246-000, Brazil
Conditions
Explore the condition pages connected to this study.